bpc 157 clinical trial human study Wolverine Stack: BPC-157 & TB-500 Guide for Recovery, Tissue Healing, and Muscle PreservationMusculoskeletal Key Quantity:6-Pack Patches Limitless Biotech

bpc 157 clinical trial human study Wolverine Stack: BPC-157 & TB-500 Guide for Recovery, Tissue Healing, and Muscle PreservationMusculoskeletal Key Quantity:6-Pack Patches Limitless Biotech

Limitless Biotech

Unfortunately, the answer is no And this is a very important point, this is where we start to see the limitations of extrapolating data from other drugs When you look at patients who are taking GH, they’re usually taking something on the order of 1-2 units per day So they’re taking small daily doses, and this seems to be beneficial because they’re not seeing these huge spikes in IGF-1 And most of them are not having any issues with blood sugar Likewise, we know that the patients with HIV who are taking it for lipodystrophy, they’re typically taking average doses of about 1.4 mg/day of tesamorelin, and again, they’re tolerating that pretty well So in theory, you could look at the GH and IGF levels with those treatments and see how they compare to what you might see with CJC Peter points out the lack of data, “ We’d love to be able to look at that method of dosing, but unfortunately, most of the human data for CJC that characterize GH and IGF-1 are changes with the DAC formulation, which has the long half-life and produces sustained exposure

Patches

Quantity:6-Pack

You start low